Inhalation of 2, 4-di-tert-butylphenol-Loaded micelles suppresses respiratory syncytial virus infection in mice
In this study, we explored the anti-RSV potential of 2, 4-Di-tert-butylphenol (2, 4-DTBP), a compound derived from Houttuynia cordata Thunb. To overcome the poor solubility of 2, 4-DTBP, we encapsulated it in polymeric micelles and delivered it by inhalation. We found that 2, 4-DTBP-loaded micelles inhibited RSV infection in vitro and improved survival, lung pathology, and viral clearance in RSV-infected mice. Our results suggested that 2, 4-DTBP-loaded micelle is a promising novel therapeutic agent for RSV infection.PMID:38608838 | DOI:10.1016/j.antiviral.2024.105880 (Source: Antiviral Research)
Source: Antiviral Research - April 12, 2024 Category: Virology Authors: Mingyang Guo Jianqing Peng Pengcheng Guo Qin Wang Lin Zhang Huyan Shen Fang Chen Pingping Zhang Siyu Lin Han Gao Hong Peng Rong Mou Jiandong Huang Jianxin Wang Yu-Si Luo Ke Zhang Source Type: research
Inhalation of 2, 4-di-tert-butylphenol-Loaded micelles suppresses respiratory syncytial virus infection in mice
In this study, we explored the anti-RSV potential of 2, 4-Di-tert-butylphenol (2, 4-DTBP), a compound derived from Houttuynia cordata Thunb. To overcome the poor solubility of 2, 4-DTBP, we encapsulated it in polymeric micelles and delivered it by inhalation. We found that 2, 4-DTBP-loaded micelles inhibited RSV infection in vitro and improved survival, lung pathology, and viral clearance in RSV-infected mice. Our results suggested that 2, 4-DTBP-loaded micelle is a promising novel therapeutic agent for RSV infection.PMID:38608838 | DOI:10.1016/j.antiviral.2024.105880 (Source: Antiviral Research)
Source: Antiviral Research - April 12, 2024 Category: Virology Authors: Mingyang Guo Jianqing Peng Pengcheng Guo Qin Wang Lin Zhang Huyan Shen Fang Chen Pingping Zhang Siyu Lin Han Gao Hong Peng Rong Mou Jiandong Huang Jianxin Wang Yu-Si Luo Ke Zhang Source Type: research
Drug delivery system based on metal-organic framework improved 5-Fluorouracil against spring viremia of carp virus
In this study, we selected 5-Fluorouracil (5-Fu) as the drug model based on zeolitic imidazolate framework-8 (ZIF-8) to construct a drug delivery system (5-Fu@ZIF-8), and the anti-SVCV activity was detected in vitro and in vivo. The results showed 5-Fu@ZIF-8 was uniform cubic particle with truncated angle and smooth surface, and the particle size was 90 nm. The anti-SVCV activity in vitro results showed that the highest inhibition rate of 5-Fu was 77.93% at 40 mg/L and the inhibitory concentration at half-maximal activity (IC50) was 20.86 mg/L. For 5-Fu@ZIF-8, the highest inhibition rate was 91.36% at 16 mg/L, and the IC50...
Source: Antiviral Research - April 11, 2024 Category: Virology Authors: Liang Zhao Wei-Ze Wang Tian-Tian Jiang Tian-Zi Sun Bo Liu Bin Zhu Source Type: research
Drug delivery system based on metal-organic framework improved 5-Fluorouracil against spring viraemia of carp virus
In this study, we selected 5-Fluorouracil (5-Fu) as the drug model based on zeolitic imidazolate framework-8 (ZIF-8) to construct a drug delivery system (5-Fu@ZIF-8), and the anti-SVCV activity was detected in vitro and in vivo. The results showed 5-Fu@ZIF-8 was uniform cubic particle with truncated angle and smooth surface, and the particle size was 90 nm. The anti-SVCV activity in vitro results showed that the highest inhibition rate of 5-Fu was 77.93% at 40 mg/L and the inhibitory concentration at half-maximal activity (IC50) was 20.86 mg/L. For 5-Fu@ZIF-8, the highest inhibition rate was 91.36% at 16 mg/L, and the IC50...
Source: Antiviral Research - April 11, 2024 Category: Virology Authors: Liang Zhao Wei-Ze Wang Tian-Tian Jiang Tian-Zi Sun Bo Liu Bin Zhu Source Type: research
Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses
Antiviral Res. 2024 Apr 9;226:105879. doi: 10.1016/j.antiviral.2024.105879. Online ahead of print.ABSTRACTTreatment options for COVID-19 remain limited. Here, we report the optimization of an siRNA targeting the highly conserved leader region of SARS-CoV-2. The siRNA was rendered nuclease resistant by the introduction of modified nucleotides without loss of activity. Importantly, the siRNA also retained its inhibitory activity against the emerged omicron sublineage variant BA.2, which occurred after the siRNA was designed and is resistant to other antiviral agents such as antibodies. In addition, we show that a second high...
Source: Antiviral Research - April 10, 2024 Category: Virology Authors: Beatrice Tolksdorf Julian Heinze Daniela Niemeyer Viola R öhrs Johanna Berg Christian Drosten Jens Kurreck Source Type: research
Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses
Antiviral Res. 2024 Apr 8:105879. doi: 10.1016/j.antiviral.2024.105879. Online ahead of print.ABSTRACTTreatment options for COVID-19 remain limited. Here, we report the optimization of an siRNA targeting the highly conserved leader region of SARS-CoV-2. The siRNA was rendered nuclease resistant by the introduction of modified nucleotides without loss of activity. Importantly, the siRNA also retained its inhibitory activity against the emerged omicron sublineage variant BA.2, which occurred after the siRNA was designed and is resistant to other antiviral agents such as antibodies. In addition, we show that a second highly a...
Source: Antiviral Research - April 10, 2024 Category: Virology Authors: Beatrice Tolksdorf Julian Heinze Daniela Niemeyer Viola R öhrs Johanna Berg Christian Drosten Jens Kurreck Source Type: research
Characterisation of ten NS2B-NS3 proteases: Paving the way for pan-flavivirus drugs
In this study, we characterised recombinant NS2B-NS3 proteases from ten flaviviruses including three unreported proteases from the Usutu, Kyasanur forest disease and Powassan viruses. All protease constructs comprise a covalent Gly4-Ser-Gly4 linker connecting the NS3 serine protease domain with its cofactor NS2B. We conducted a comprehensive cleavage site analysis revealing areas of high conversion. While all proteases were active in enzymatic assays, we noted a 1000-fold difference in catalytic efficiency across proteases from different flaviviruses. Two bicyclic peptide inhibitors displayed anti-pan-flaviviral protease a...
Source: Antiviral Research - April 6, 2024 Category: Virology Authors: Saan Voss J örg Rademann Christoph Nitsche Source Type: research
Characterisation of ten NS2B-NS3 proteases: Paving the way for pan-flavivirus drugs
In this study, we characterised recombinant NS2B-NS3 proteases from ten flaviviruses including three unreported proteases from the Usutu, Kyasanur forest disease and Powassan viruses. All protease constructs comprise a covalent Gly4-Ser-Gly4 linker connecting the NS3 serine protease domain with its cofactor NS2B. We conducted a comprehensive cleavage site analysis revealing areas of high conversion. While all proteases were active in enzymatic assays, we noted a 1000-fold difference in catalytic efficiency across proteases from different flaviviruses. Two bicyclic peptide inhibitors displayed anti-pan-flaviviral protease a...
Source: Antiviral Research - April 6, 2024 Category: Virology Authors: Saan Voss J örg Rademann Christoph Nitsche Source Type: research
Characterisation of ten NS2B-NS3 proteases: Paving the way for pan-flavivirus drugs
In this study, we characterised recombinant NS2B-NS3 proteases from ten flaviviruses including three unreported proteases from the Usutu, Kyasanur forest disease and Powassan viruses. All protease constructs comprise a covalent Gly4-Ser-Gly4 linker connecting the NS3 serine protease domain with its cofactor NS2B. We conducted a comprehensive cleavage site analysis revealing areas of high conversion. While all proteases were active in enzymatic assays, we noted a 1000-fold difference in catalytic efficiency across proteases from different flaviviruses. Two bicyclic peptide inhibitors displayed anti-pan-flaviviral protease a...
Source: Antiviral Research - April 6, 2024 Category: Virology Authors: Saan Voss J örg Rademann Christoph Nitsche Source Type: research
Characterisation of ten NS2B-NS3 proteases: Paving the way for pan-flavivirus drugs
In this study, we characterised recombinant NS2B-NS3 proteases from ten flaviviruses including three unreported proteases from the Usutu, Kyasanur forest disease and Powassan viruses. All protease constructs comprise a covalent Gly4-Ser-Gly4 linker connecting the NS3 serine protease domain with its cofactor NS2B. We conducted a comprehensive cleavage site analysis revealing areas of high conversion. While all proteases were active in enzymatic assays, we noted a 1000-fold difference in catalytic efficiency across proteases from different flaviviruses. Two bicyclic peptide inhibitors displayed anti-pan-flaviviral protease a...
Source: Antiviral Research - April 6, 2024 Category: Virology Authors: Saan Voss J örg Rademann Christoph Nitsche Source Type: research
Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp
Antiviral Res. 2024 Apr 3:105873. doi: 10.1016/j.antiviral.2024.105873. Online ahead of print.ABSTRACTIn the 1990s, monoclonal antibodies (mAbs) progressed from scientific tools to advanced therapeutics, particularly for the treatment of cancers and autoimmune and inflammatory disorders. In the arena of infectious disease, the inauguration of mAbs as a post-exposure treatment in humans against Ebola virus (EBOV) occurred in response to the 2013-2016 West Africa outbreak. This review recounts the history of a candidate mAb treatment, ZMapp, beginning with its emergency use in the 2013-2016 outbreak and advancing to randomiz...
Source: Antiviral Research - April 5, 2024 Category: Virology Authors: Gary Wong Kathrina Mae Bienes Ara Xiii Hugues Fausther-Bovendo Gary P Kobinger Source Type: research
Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp
Antiviral Res. 2024 Apr 3:105873. doi: 10.1016/j.antiviral.2024.105873. Online ahead of print.ABSTRACTIn the 1990s, monoclonal antibodies (mAbs) progressed from scientific tools to advanced therapeutics, particularly for the treatment of cancers and autoimmune and inflammatory disorders. In the arena of infectious disease, the inauguration of mAbs as a post-exposure treatment in humans against Ebola virus (EBOV) occurred in response to the 2013-2016 West Africa outbreak. This review recounts the history of a candidate mAb treatment, ZMapp, beginning with its emergency use in the 2013-2016 outbreak and advancing to randomiz...
Source: Antiviral Research - April 5, 2024 Category: Virology Authors: Gary Wong Kathrina Mae Bienes Ara Xiii Hugues Fausther-Bovendo Gary P Kobinger Source Type: research
Supplementation of seasonal vaccine with multi-subtype neuraminidase and M2 ectodomain virus-like particle improves protection against homologous and heterologous influenza viruses in aged mice
Antiviral Res. 2024 Mar 30;225:105877. doi: 10.1016/j.antiviral.2024.105877. Online ahead of print.ABSTRACTThe conventional inactivated split seasonal influenza vaccine offers low efficacy, particularly in the elderly and against antigenic variants. Here, to improve the efficacy of seasonal vaccination for the elderly population, we tested whether supplementing seasonal bivalent (H1N1 + H3N2) split (S) vaccine with M2 ectodomain repeat and multi-subtype consensus neuraminidase (NA) proteins (N1 NA + N2 NA + flu B NA) on a virus-like particle (NA-M2e) would induce enhanced cross-protection against different influenza viruse...
Source: Antiviral Research - April 1, 2024 Category: Virology Authors: Jannatul Ruhan Raha Ki-Hye Kim Noopur Bhatnagar Rong Liu Chau Thuy Tien Le Bo Ryoung Park Phillip Grovenstein Surya Sekhar Pal Eun-Ju Ko Chong Hyun Shin Bao-Zhong Wang Sang-Moo Kang Source Type: research
Supplementation of seasonal vaccine with multi-subtype neuraminidase and M2 ectodomain virus-like particle improves protection against homologous and heterologous influenza viruses in aged mice
Antiviral Res. 2024 Mar 30:105877. doi: 10.1016/j.antiviral.2024.105877. Online ahead of print.ABSTRACTThe conventional inactivated split seasonal influenza vaccine offers low efficacy, particularly in the elderly and against antigenic variants. Here, to improve the efficacy of seasonal vaccination for the elderly population, we tested whether supplementing seasonal bivalent (H1N1 + H3N2) split (S) vaccine with M2 ectodomain repeat and multi-subtype consensus neuraminidase (NA) proteins (N1 NA + N2 NA + flu B NA) on a virus-like particle (NA-M2e) would induce enhanced cross-protection against different influenza viruses in...
Source: Antiviral Research - April 1, 2024 Category: Virology Authors: Jannatul Ruhan Raha Ki-Hye Kim Noopur Bhatnagar Rong Liu Chau Thuy Tien Le Bo Ryoung Park Phillip Grovenstein Surya Sekhar Pal Eun-Ju Ko Chong Hyun Shin Bao-Zhong Wang Sang-Moo Kang Source Type: research
Supplementation of seasonal vaccine with multi-subtype neuraminidase and M2 ectodomain virus-like particle improves protection against homologous and heterologous influenza viruses in aged mice
Antiviral Res. 2024 Mar 30:105877. doi: 10.1016/j.antiviral.2024.105877. Online ahead of print.ABSTRACTThe conventional inactivated split seasonal influenza vaccine offers low efficacy, particularly in the elderly and against antigenic variants. Here, to improve the efficacy of seasonal vaccination for the elderly population, we tested whether supplementing seasonal bivalent (H1N1 + H3N2) split (S) vaccine with M2 ectodomain repeat and multi-subtype consensus neuraminidase (NA) proteins (N1 NA + N2 NA + flu B NA) on a virus-like particle (NA-M2e) would induce enhanced cross-protection against different influenza viruses in...
Source: Antiviral Research - April 1, 2024 Category: Virology Authors: Jannatul Ruhan Raha Ki-Hye Kim Noopur Bhatnagar Rong Liu Chau Thuy Tien Le Bo Ryoung Park Phillip Grovenstein Surya Sekhar Pal Eun-Ju Ko Chong Hyun Shin Bao-Zhong Wang Sang-Moo Kang Source Type: research
